EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease

Stefan Schreiber iD, Scott D Lee iD, C Janneke van der Woude, Ignacio Marín-Jiménez, Douglas C Wolf, Elisabeth Schnoy, Bruce Salzberg, Christopher Busse, Maciej Nazar, Tony Ma, Stephan Borghorst, Christopher Gasink und 5 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf163 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Stefan Schreiber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The POWER study (NCT03782376) evaluated efficacy and safety of a single ustekinumab intravenous (IV) reinduction dose versus placebo under continued ustekinumab subcutaneous (SC) treatment in adult patients with moderately to severely active Crohn’s disease who demonstrated a secondary loss of response to ustekinumab every 8 weeks (q8w) maintenance therapy.

Methods

Patients were randomly assigned 1:1 at Week 0 to ustekinumab IV reinduction (ustekinumab ∼6 mg/kg and SC placebo) or continuous maintenance (IV placebo and SC ustekinumab 90 mg q8w). Clinical and biomarker assessments occurred at Weeks 0, 8, 16, and 24 with optional ileocolonoscopy at Weeks 0 and16. The primary endpoint was clinical response (≥100-point decrease from baseline Crohn’s Disease Activity Index [CDAI] score or CDAI <150) at Week 16. Safety events were analyzed through Week 36 and serum samples were collected for pharmacokinetic analyses and anti-ustekinumab antibody detection.

Results

Overall, 215 patients were randomized: 108 to the IV reinduction group and 107 to the SC group. In the IV reinduction group, 49.1% achieved clinical response at Week 16 versus 37.4% in the SC group (adjusted treatment difference 11.5% [95% CI: −1.5%, 24.5%; P = .089]). Proportions of patients with endoscopic remission and improvement, normalization of inflammatory biomarkers, and improvement in IBDQ score were greater in the IV reinduction group vs the SC group. No new safety signals were identified.

Conclusions

Although the primary endpoint of clinical response was not met at Week 16, ustekinumab IV reinduction showed numerical improvements in objective endpoints including inflammatory biomarkers and endoscopic outcomes compared with SC maintenance therapy. Safety and immunogenicity results were consistent with the established profile of ustekinumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansFemaleAdultMaleDouble-Blind MethodMiddle AgedTreatment OutcomeYoung AdultBiomarkersRemission InductionAdministration, IntravenousSeverity of Illness Index

Stichwörter der Autor:innen

Crohn’s diseaseintravenous reinductionustekinumab

Substanzen

UstekinumabBiomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Division of Gastroenterology, University of Washington, Seattle, WA, United States.
  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Gastroenterology Unit, Hospital Universitario Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain.
  • Center for Crohn's Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, United States.
  • Internal Medicine III, Gastroenterology, University Hospital of Augsburg, Augsburg, Germany.

ORCID-Profile: Stefan Schreiber, Scott D Lee

Förderung

  • Johnson & Johnson

Zitieren

APA

Schreiber, S., Lee, S. D., van der Woude, C. J., Marín-Jiménez, I., Wolf, D. C., Schnoy, E., Salzberg, B., Busse, C., Nazar, M., Ma, T., Borghorst, S., Gasink, C., Baker, T., Godwin, B., Adedokun, O. J., Feagan, B. G., & POWER Study Group (2025). Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf163

Vancouver

Schreiber S, Lee SD, van der Woude CJ, Marín-Jiménez I, Wolf DC, Schnoy E, et al. Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf163

BibTeX
@article{Schreiber2025,
  author = {Schreiber, Stefan and Lee, Scott D and van der Woude, C Janneke and Marín-Jiménez, Ignacio and Wolf, Douglas C and Schnoy, Elisabeth and Salzberg, Bruce and Busse, Christopher and Nazar, Maciej and Ma, Tony and Borghorst, Stephan and Gasink, Christopher and Baker, Thomas and Godwin, Bridget and Adedokun, Omoniyi J and Feagan, Brian G and POWER Study Group, POWER Study Group},
  title = {Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf163}
}
Kostenlos starten →